# US 2021/0069152 A1 · Methods for treating heterotopic ossification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069152 A1
- Document ID: US20210069152A1
- Status: Published application
- Kind: A1
- Application number: 16/950,604
- Filed: 2020-11-17
- Published: 2021-03-11
- Earliest claimed: 2016-06-08
- Assignees: Clementia Pharmaceuticals Inc.
- Applicants: Clementia Pharmaceuticals Inc.
- Inventors: Clarissa Desjardins; Donna Roy Grogan; Jeffrey Neal Packman; Mark Harnett
- Web page: https://patentgrep.com/patent/US20210069152A1

## CPC

- A61K 31/415: 1,2-Diazoles
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.

## Claims

### Claim 1

A method of reducing heterotopic ossification in a subject with fibrodysplasia ossificans progressiva, said method comprising during a period when the subject is experiencing at least one flare-up symptom: (i) orally administering to the subject an amount of 20±1.0 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of 20 to 40 days, and (ii) after the period of 20 to 40 days, orally administering to the subject an amount of 10±1.0 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of 14 to 112 days.

### Claim 2 (depends on 1)

The method of claim 1, wherein the 10±1.0 mg amount is administered daily for a period of 14 to 84 days.

### Claim 3 (depends on 2)

The method of claim 2, wherein at the end of 84 days the 10±1.0 mg amount is administered daily for an additional 28 days if the subject continues to experience at least one flare-up symptom.

### Claim 4 (depends on 1)

The method of claim 1, wherein the 10±1.0 mg amount is administered daily for a period of 14 to 56 days.

### Claim 5 (depends on 1)

The method of claim 1, wherein the 10±1.0 mg amount is administered daily for a period of 56 days.

### Claim 6 (depends on 1)

The method of claim 1, wherein the 10±1.0 mg amount is administered daily for a period of 56 days, and for an additional 28 days if the subject continues to experience at least one flare-up symptom.

### Claim 7 (depends on 1)

The method of claim 1, wherein the 10±1.0 mg amount is administered daily for a period of 112 days.

### Claim 8 (depends on 1)

The method of claim 1, wherein the 20±1.0 mg amount is administered daily for a period of 28±4 days.

### Claim 9 (depends on 1)

The method of claim 1, wherein the 20±1.0 mg amount is administered daily for a period of 28 days.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject weighs greater than 60 kg.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject has a skeletal maturity of 90% or greater.

### Claim 12 (depends on 1)

The method of claim 1, further comprising administering to the subject an antihistamine.

### Claim 13 (depends on 12)

The method of claim 12, wherein the antihistamine is administered topically.

### Claim 14 (depends on 12)

The method of claim 12, wherein the antihistamine is administered systemically.

### Claim 15 (depends on 1)

The method of claim 1, further comprising administering to the skin of the subject an emollient.

### Claim 16 (depends on 1)

The method of claim 1, wherein the at least one flare-up symptom is chosen from swelling, pain, erythema, warmth, stiffness, and decreased range of motion.

### Claim 17 (depends on 1)

The method of claim 1, wherein the amount administered daily is of palovarotene.

### Claim 18 (depends on 1)

The method of claim 1, wherein the amount administered daily is of a pharmaceutically acceptable salt of palovarotene.
